The glymphatic system takes its name from the glial cells that support it, and it was first described as a brain-wide network of perivascular channels along which cerebrospinal fluid flows into brain tissue and interstitial fluid flows out. During sleep, these channels widen and clearance ramps up, carrying away amyloid-beta, tau, and other waste products. In Parkinson’s disease, the pathological hallmark is the accumulation of misfolded alpha-synuclein protein inside neurons, and scientists have long suspected that a failing glymphatic system could allow this protein to accumulate and spread faster, accelerating the disease process. What the new study adds is a direct clinical link: patients whose glymphatic clearance appears most impaired are precisely the ones whose drooling is worst.

To probe that connection, the team enrolled 72 people with Parkinson’s disease, split evenly into 36 patients who experienced drooling and 36 who did not, alongside 38 age-matched healthy controls. Every participant underwent magnetic resonance imaging and a battery of standardized clinical assessments covering disease severity, cognition, mood, and, for the patients with drooling, the severity and frequency of their symptoms using dedicated Parkinson’s-specific scales such as the Sialorrhea Clinical Scale for Parkinson’s disease and the Drooling Severity and Frequency Scale. The design allowed the researchers to compare three groups head to head and to ask which imaging features best separated droolers from non-droolers.

The centerpiece of the imaging analysis was a technique called diffusion tensor image analysis along the perivascular space, abbreviated DTI-ALPS. Diffusion tensor imaging tracks how water molecules diffuse through tissue, and because water moves more freely along the perivascular channels of the glymphatic system than across them, the ALPS index serves as a proxy for how efficiently fluid travels along those clearance routes. A lower ALPS index implies more restricted diffusion along the perivascular spaces, and by inference, more sluggish glymphatic function. The method has been applied in studies of Alzheimer’s disease, normal aging, and sleep disorders, but its use to stratify symptoms within Parkinson’s disease is still relatively novel.

The results were striking. Patients with drooling showed significantly lower ALPS indices on both the left and right hemispheres, as well as a lower bilateral average, than patients without drooling and than the healthy controls. The differences between the drooling and non-drooling Parkinson’s groups reached statistical significance on all three measures, with p values of 0.032 for the left index and 0.004 for both the right index and the bilateral average, while the gap between the drooling group and the healthy controls was even wider, with p values below 0.001 across the board. In other words, among people at the same stage of the same disease, those with drooling carried a distinct and measurable signature of impaired brain fluid dynamics.

The team also examined two other markers of glymphatic health. They measured the volume of the choroid plexus, the vascular tissue in the brain ventricles that produces cerebrospinal fluid, normalized to total intracranial volume. Both Parkinson’s groups, with and without drooling, showed significantly larger choroid plexus volumes relative to healthy controls, with p values of 0.001 and 0.006 respectively, suggesting that choroid plexus enlargement marks the disease itself rather than the drooling symptom specifically. Enlarged perivascular spaces, visible on MRI as dilated fluid-filled channels and another candidate readout of glymphatic drainage, showed no significant differences among the three groups, indicating that this particular structural marker was not sensitive to drooling status in this cohort.

Correlation analyses sharpened the story further. Across the patients, lower ALPS indices were associated with greater overall disease severity and, critically, with more severe drooling symptoms. The researchers then turned to receiver operating characteristic analysis, a standard statistical tool for testing how well a measurement discriminates between two groups, and found that the bilateral average ALPS index was the best single separator of Parkinson’s patients with drooling from those without, achieving an area under the curve of 0.725. A final multivariate logistic regression, which adjusted for other clinical variables, confirmed that the bilateral ALPS index stood as an independent predictor of drooling, with an odds ratio of 0.063 and a 95 percent confidence interval of 0.004 to 0.938 and a p value of 0.045. Because the odds ratio falls below one, it indicates that higher, healthier glymphatic function is associated with lower odds of drooling.

What might connect a brain-wide clearance system to saliva pooling at the corner of the mouth? The authors point to alpha-synuclein. Pathological alpha-synuclein in Parkinson’s disease is not confined to the substantia nigra; it spreads through brainstem and autonomic circuits, including regions that govern swallowing and salivary control. If glymphatic dysfunction permits pathological protein to accumulate more readily in those circuits, the autonomic and motor regulation of swallowing could falter, allowing saliva to collect and spill. The choroid plexus enlargement observed in both patient groups adds a second thread, since the choroid plexus is the source of the cerebrospinal fluid that drives glymphatic flow, and inflammatory or age-related changes in this tissue could compromise the driving pressure of the whole clearance network. The researchers caution that their findings provide indirect, in vivo evidence of this mechanism rather than a direct demonstration, but the concordance between the imaging signal and the clinical symptom is difficult to dismiss.

The practical implications are considerable. Drooling affects a large share of Parkinson’s patients, causing skin irritation around the mouth, increased risk of aspiration and chest infections, and profound embarrassment that leads many people to withdraw from social life. Current treatments, from anticholinergic drugs to botulinum toxin injections into the salivary glands, target the downstream output rather than any upstream neurological cause. If the ALPS index can be validated in larger and more diverse cohorts, it could function as an imaging biomarker that flags patients at risk of developing or worsening drooling, allowing earlier intervention and giving trial designers an objective measure for testing therapies aimed at restoring glymphatic function. The authors suggest that the index may prove useful for predicting both the occurrence and the progression of the symptom over time.

The study has limits that the team acknowledges. With 72 patients drawn from a single center, the cohort is modest, and the cross-sectional design captures a snapshot rather than the arc of disease, so it cannot yet prove that glymphatic decline precedes drooling rather than accompanying it. The ALPS index itself remains an indirect measure, and its interpretation can be influenced by head position, imaging parameters, and age. Even so, the convergence of evidence, from group differences and symptom correlations to independent predictive value in regression, makes a compelling case that the brain’s drainage system matters for one of Parkinson’s most underappreciated symptoms. As glymphatic research moves from animal models toward the clinic, this study signals that waste clearance may hold explanatory power well beyond neurodegeneration itself, reaching into the everyday, embodied symptoms that shape patients’ lives.

Subject of Research: Glymphatic system dysfunction and drooling severity in Parkinson's disease

Article Title: Glymphatic dysfunction predicts drooling severity in Parkinson’s disease

Article References: Huang, T., Tian, Y., Xia, Y., Yao, J., Gao, Q., Shang, S., Deng, T., Muthaiah, V. P., Zhang, Y., Yin, X., & Chen, Y. (2026). Glymphatic dysfunction predicts drooling severity in Parkinson’s disease. BMC Medicine. https://doi.org/10.1186/s12916-026-05299-5

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05299-5

Keywords: Parkinson's disease, glymphatic system, drooling, sialorrhea, DTI-ALPS, MRI biomarker, alpha-synuclein, choroid plexus, perivascular spaces, neurodegeneration, non-motor symptoms, brain clearance

The glymphatic system, first described in animal studies little more than a decade ago, is a network of channels that runs alongside blood vessels, known as perivascular spaces, through which cerebrospinal fluid flushes metabolic waste out of brain tissue. During sleep, this clearance system ramps up its activity, washing away proteins and byproducts that accumulate during waking hours. When glymphatic function falters, waste products linger, and scientists have linked such dysfunction to Alzheimer’s disease, small vessel disease, and sleep disorders. Whether the same machinery is disturbed in migraine has been an open question, and the new study, published in BMC Medical Imaging, offers one of the most comprehensive noninvasive assessments to date.

Researchers led by Ying Yang and Huang Xu of the First Affiliated Hospital of the University of Science and Technology of China enrolled 123 participants: 38 patients with episodic migraine, who experience headaches on fewer than 15 days per month; 46 patients with chronic migraine, defined by headaches on 15 or more days per month; and 39 healthy controls. Rather than relying on a single imaging marker, the team deployed a multimodal magnetic resonance imaging strategy that captured three complementary windows into glymphatic activity, allowing them to probe the system from structural, diffusion, and functional perspectives simultaneously.

The first measure was the diffusion tensor image analysis along the perivascular space, or DTI-ALPS index. This technique exploits the fact that water molecules diffuse more freely along the channels surrounding vessels in the brain’s deep white matter. By measuring diffusion in directions perpendicular to the ventricle walls and comparing it with diffusion along the medullary vessels, the index provides an indirect estimate of how efficiently fluid moves through perivascular spaces. A lower DTI-ALPS index is interpreted as reduced glymphatic clearance capacity. The second measure was choroid plexus volume, the size of the tissue structures that produce cerebrospinal fluid, which researchers have proposed as a marker of fluid production and inflammatory activity. The third was BOLD-CSF coupling, a functional metric that quantifies how tightly fluctuations in the blood oxygen level dependent signal, a proxy for neural activity, are synchronized with the pulsing motion of cerebrospinal fluid, a relationship thought to reflect the driving force that pushes fluid through the glymphatic channels.

The results were striking in their pattern of selectivity. After adjusting for age, sex, years of education, and other relevant covariates, the researchers found that both the left, right, and mean DTI-ALPS indices were significantly lower in patients with episodic migraine and in patients with chronic migraine compared with healthy controls, differences that held up under stringent Bonferroni correction for multiple comparisons. In other words, the diffusion signature of impaired perivascular clearance was present in both migraine groups, suggesting that altered glymphatic function may be a feature of the disease across its spectrum rather than a consequence of chronification alone.

The functional measure told a more nuanced story. Patients with chronic migraine showed significantly weaker global BOLD-CSF coupling than healthy controls, again surviving Bonferroni correction. When the researchers broke the coupling analysis down to the level of individual brain networks, they found that chronic migraine patients exhibited weaker coupling specifically within the dorsal attention network, a circuit involved in directing attention to external stimuli that has previously been implicated in migraine pathophysiology. However, this network-level difference did not survive false discovery rate correction, meaning it should be treated as a suggestive rather than definitive finding. Notably, episodic migraine patients did not show significant global coupling differences, hinting that the functional component of glymphatic impairment may deepen as the disease becomes chronic.

Perhaps the most unexpected result concerned the choroid plexus. Contrary to the hypothesis that cerebrospinal fluid production structures would be altered in migraine, choroid plexus volume did not differ significantly across the three groups. Yet the volume measure was not entirely inert. In patients with chronic migraine, partial correlation analyses revealed significant negative correlations between the DTI-ALPS index and choroid plexus volume metrics, meaning that patients with larger fluid-producing structures tended to show weaker perivascular diffusion markers. This inverse relationship, significant at corrected thresholds, suggests that different components of the glymphatic machinery may compensate for one another or that a common underlying process shapes both measures in chronic disease.

The clinical correlations added another layer of complexity. In episodic migraine patients, the researchers observed negative associations between scores on the Headache Impact Test-6, a widely used questionnaire measuring the burden of headaches on daily life, and choroid plexus volume metrics. Patients reporting greater headache impact tended to have smaller choroid plexus volumes. However, these associations did not survive correction for multiple comparisons, so the authors were careful not to overstate them. No similarly robust relationships emerged between imaging measures and clinical scales in the chronic migraine group, underscoring how difficult it remains to link brain waste-clearance markers to the day-to-day experience of headache severity.

What emerges from the study is a picture of heterogeneity rather than uniform breakdown. The structural diffusion marker was impaired in both migraine subtypes, the functional coupling marker was impaired only in chronic migraine, and the fluid production marker was preserved in volume yet inversely related to diffusion measures in chronic patients. The authors argue that this pattern demonstrates the inadequacy of any single MRI metric for characterizing glymphatic-related alterations in migraine and makes the case for a multidimensional imaging framework that combines structural, diffusion, and functional measures. Such a framework, they suggest, could better capture the variable ways in which waste clearance is disturbed across individuals and disease stages.

The findings carry broader implications for how scientists think about migraine biology. If glymphatic dysfunction is genuinely involved, it could connect migraine to a growing list of conditions in which impaired brain clearance plays a role, and it might explain long-standing clinical observations such as the strong association between migraine and sleep disturbances. It also raises the possibility, still speculative, that interventions targeting sleep quality, fluid dynamics, or perivascular health could one day complement existing migraine therapies. For now, the study is cross-sectional, capturing a single moment in time, so it cannot establish whether glymphatic changes cause migraine, result from it, or reflect a shared mechanism. Longitudinal studies tracking patients as migraine progresses from episodic to chronic forms, along with studies that directly validate the imaging markers against invasive measures of clearance, will be needed to settle those questions. But by showing that the brain’s washing system leaves detectable fingerprints in routine MRI, the work opens a tangible new avenue for understanding one of medicine’s most common and stubborn neurological disorders.

Subject of Research: Glymphatic system dysfunction measured by multimodal MRI in episodic and chronic migraine

Article Title: The heterogeneity of glymphatic-related MRI alterations in migraine: a cross-sectional multimodal study

Article References: Yang, Y., Xu, H., Wu, J., Deng, Z., Wu, Y., Fu, L., Wang, Z., Gao, F., Wen, J., Liu, Y., Gui, W., & Wei, W. (2026). The heterogeneity of glymphatic-related MRI alterations in migraine: a cross-sectional multimodal study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02926-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02926-8

Keywords: migraine, glymphatic system, MRI, DTI-ALPS index, BOLD-CSF coupling, choroid plexus volume, chronic migraine, episodic migraine, cerebrospinal fluid, neuroimaging, perivascular spaces, headache

The subarachnoid space is best known as the layer between two protective membranes surrounding the brain and spinal cord. It contains cerebrospinal fluid, or CSF, which cushions the central nervous system and participates in the movement of nutrients, signaling molecules and waste products. Within this environment, arteries and veins travel along the brain’s surface and branch into deeper tissue. The spaces surrounding some of these vessels form specialized anatomical corridors that may influence fluid movement and communication between the brain’s vascular and fluid systems.

Researchers have long recognized that fluid does not circulate through the brain in a simple, open plumbing network. Instead, CSF moves through interconnected compartments, while blood vessels create boundaries and pathways that can shape local flow. Perivascular spaces are particularly important because they lie at the interface of vascular pulsation, tissue structure and fluid transport. Changes in their size, shape or visibility may reflect alterations in pressure, inflammation, vascular function or the clearance of metabolic waste.

The phrase “perivascular subarachnoid spaces” refers specifically to spaces associated with vessels in the subarachnoid compartment, rather than the more commonly discussed perivascular spaces located within the brain’s white matter and deep gray matter. Distinguishing these regions is technically important. Similar-looking spaces can arise in different anatomical locations and may have different biological meanings. A method that can reliably identify and characterize them could help researchers separate normal anatomical variation from changes linked to disease.

The study’s central significance lies in its non-invasive approach. Instead of relying on tissue removal or direct surgical access, non-invasive characterization generally uses advanced medical imaging and quantitative analysis to extract anatomical and physiological information from living participants. Imaging can reveal the geometry of fluid spaces, their relationship to nearby vessels and, in some circumstances, indirect signs of fluid movement. Such measurements are especially valuable for studying structures that are too small, delicate or inaccessible to investigate directly in routine clinical practice.

This type of research could also help clarify how the brain’s waste-clearance systems operate. The glymphatic system, a proposed network involving CSF and interstitial fluid, has attracted intense interest because it may help transport metabolic by-products away from neural tissue. Perivascular pathways are thought to be involved in this process, although their exact roles, direction of flow and relationship to other fluid compartments remain active areas of investigation. Better imaging of the spaces around surface vessels may provide data needed to test competing explanations rather than relying solely on theoretical models.

The potential medical relevance is broad. Disturbances in cerebrospinal-fluid dynamics and vascular function appear in conditions ranging from hydrocephalus and stroke to small-vessel disease, traumatic brain injury and neurodegenerative disorders. Enlarged or altered perivascular spaces have also been reported in association with aging and several brain diseases. However, an imaging finding is not automatically a diagnostic marker. Researchers must determine how much variation is normal, whether measurements are reproducible between scanners and observers, and whether changes in these spaces predict symptoms or clinical outcomes.

A reliable non-invasive method could eventually make it easier to compare the brain’s fluid compartments across individuals and over time. Longitudinal imaging might allow scientists to observe whether perivascular structures change with age, sleep, blood-pressure control or disease progression. It could also support studies of therapies designed to influence vascular pulsatility, CSF circulation or waste clearance. For now, the value of the work is primarily methodological: before a biological structure can become a biomarker, investigators need a consistent way to see and measure it.

The findings arrive at a moment when brain imaging is becoming increasingly quantitative. Modern scanners can generate high-resolution anatomical maps, while computational techniques can identify subtle structures and calculate their spatial relationships. Yet greater technical power also creates new challenges, including the risk of confusing imaging artifacts with anatomy and the danger of attaching biological meaning to patterns that have not been independently validated. Studies such as this one are therefore important not only because they highlight a hidden component of brain organization, but also because they help establish the measurement standards required for future research.

Perivascular subarachnoid spaces may sound like a specialized anatomical detail, but they sit at a potentially crucial crossroads linking blood vessels, cerebrospinal fluid and the brain’s protective membranes. By pursuing a non-invasive way to study them, Fultz, Ringstad, Debiasi and their colleagues are contributing to a broader effort to make the brain’s fluid circulation visible in living people. The approach does not yet transform these spaces into a clinical test, but it could provide researchers with a new tool for investigating how the brain maintains its internal environment—and what happens when that finely balanced system begins to fail.

Subject of Research: Non-invasive characterization of perivascular subarachnoid spaces in the human brain.

Article Title: Non-invasive characterization of perivascular subarachnoid spaces

Article References: Fultz, N.E., Ringstad, G., Debiasi, M. et al. “Non-invasive characterization of perivascular subarachnoid spaces.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76306-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76306-9

Keywords: perivascular subarachnoid spaces, cerebrospinal fluid, brain imaging, neuroanatomy, vascular biology, glymphatic system, non-invasive research, neurological disease